Octapharma has filed a patent for a method using CRISPR/Cas to modify genes with at least three alleles in cells. The invention also includes producing proteins in these modified cells for potential therapeutic use. GlobalData’s report on Octapharma gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Octapharma, Affinity chromatography for antibodies was a key innovation area identified from patents. Octapharma's grant share as of January 2024 was 50%. Grant share is based on the ratio of number of grants to total number of patents.
Gene modification method using crispr/cas for cells with 3 alleles
The patent application (Publication Number: US20240002841A1) describes a method for modifying genes in a cell using CRISPR/Cas technology. The method focuses on cells with at least three alleles in the target gene(s) and involves introducing insertions, deletions, or substitutions in the nucleotide sequence of the gene(s) coding and/or regulatory regions. The modification results in decreased transcription/expression of the gene(s) or production of truncated/altered enzymatic activity variants. The method can be applied to polyploid cells and targets specific genes like B4GALNT3, B4GALNT4, or glutamine synthetase.
Furthermore, the patent application includes claims related to the specific targeting sequences for genes like B4GALNT3 and B4GALNT4, as well as the use of two gRNA plasmids for each targeted position. The method is applicable to human cells or cells derived from human cells, including immortalized cells. Additionally, the application covers the production of proteins in host cells by introducing nucleic acids encoding the protein and culturing the cells to facilitate protein production. The protein produced can be a naturally occurring protein, an artificially created protein, or a fragment thereof, showcasing the versatility of the method in protein production applications.
To know more about GlobalData’s detailed insights on Octapharma, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
